BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND CARS, P49589, 833, ENSG00000110619
352 results:

  • 1. Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203.
    Watanabe T; Matsuno Y; Wakabayashi M; Maruyama D; Yamamoto K; Kubota N; Shimada K; Asagoe K; Yamaguchi M; Ando K; Ogura M; Kuroda J; Suehiro Y; Tsukasaki K; Tobinai K; Nagai H
    Hematol Oncol; 2024 May; 42(3):e3272. PubMed ID: 38595316
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Prediction model of radiotherapy outcome for Ocular Adnexal lymphoma using informative features selected by chemometric algorithms.
    Zhou M; Wang J; Shi J; Zhai G; Zhou X; Ye L; Li L; Hu M; Zhou Y
    Comput Biol Med; 2024 Mar; 170():108067. PubMed ID: 38301513
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Prognostic Value of
    Luo Y; Huang Z; Gao Z; Wang B; Zhang Y; Bai Y; Wu Q; Wang M
    Korean J Radiol; 2024 Feb; 25(2):189-198. PubMed ID: 38288898
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. How to Test Human CAR T Cells in Solid Tumors, the Next Frontier of CAR T Cell Therapy.
    Cochrane RW; Fiorentino A; Allen E; Robino RA; Quiroga J; Ferreira LMR
    Methods Mol Biol; 2024; 2748():243-265. PubMed ID: 38070118
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Constitutive Interleukin-7 Cytokine Signaling Enhances the Persistence of Epstein-Barr Virus-Specific T-Cells.
    Sharma S; Sauer T; Omer BA; Shum T; Rollins LA; Rooney CM
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958791
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. [Efficacy and Safety of Etoposide Combined with Cyclophosphamide for Autologous Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma].
    Tu ST; Zhou YL; Li F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1410-1414. PubMed ID: 37846692
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Journey of CAR T‑cells: Emphasising the concepts and advancements in breast cancer (Review).
    Kausar MA; Anwar S; El-Horany HE; Khan FH; Tyagi N; Najm MZ; Sadaf ; Eisa AA; Dhara C; Gantayat S
    Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37830150
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity.
    Faber ML; Oldham RAA; Thakur A; Rademacher MJ; Kubicka E; Dlugi TA; Gifford SA; McKillop WM; Schloemer NJ; Lum LG; Medin JA
    Front Immunol; 2023; 14():1225610. PubMed ID: 37646042
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Chimeric Antigen Receptor T Cells: Immunotherapy for the Treatment of Leukemia, lymphoma, and Myeloma.
    Rodríguez Gil de Montes AL; Spencer LM
    Mol Cancer Ther; 2023 Nov; 22(11):1261-1269. PubMed ID: 37596239
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Novel chimeric antigen receptor targets and constructs for acute lymphoblastic leukemia: Moving beyond CD19.
    Acharya L; Garg A; Rai M; Kshetri R; Grewal US; Dhakal P
    J Investig Med; 2024 Jan; 72(1):32-46. PubMed ID: 37497999
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy.
    Qi Y; Liu H; Li X; Shi Y; Mu J; Li J; Wang Y; Deng Q
    Ann Med; 2023 Dec; 55(1):2230888. PubMed ID: 37417690
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Chimeric antigen receptor T-cells: Properties, production, and quality control.
    Ramesh P; Hui HYL; Brownrigg LM; Fuller KA; Erber WN
    Int J Lab Hematol; 2023 Aug; 45(4):425-435. PubMed ID: 37337970
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. The future of CAR T-cell therapy for B-cell acute lymphoblastic leukemia in pediatrics and adolescents.
    Schultz L; Mackall CL
    Expert Opin Biol Ther; 2023; 23(7):633-640. PubMed ID: 37326236
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. CD38 as a pan-hematologic target for chimeric antigen receptor T cells.
    Glisovic-Aplenc T; Diorio C; Chukinas JA; Veliz K; Shestova O; Shen F; Nunez-Cruz S; Vincent TL; Miao F; Milone MC; June CH; Teachey DT; Tasian SK; Aplenc R; Gill S
    Blood Adv; 2023 Aug; 7(16):4418-4430. PubMed ID: 37171449
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction.
    Selli ME; Landmann JH; Terekhova M; Lattin J; Heard A; Hsu YS; Chang TC; Chang J; Warrington J; Ha H; Kingston N; Hogg G; Slade M; Berrien-Elliott MM; Foster M; Kersting-Schadek S; Gruszczynska A; DeNardo D; Fehniger TA; Artyomov M; Singh N
    Blood; 2023 Jun; 141(26):3153-3165. PubMed ID: 37130030
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway.
    Althaus J; Nilius-Eliliwi V; Maghnouj A; Döring S; Schroers R; Hudecek M; Hahn SA; Mika T
    Cancer Immunol Immunother; 2023 Aug; 72(8):2573-2583. PubMed ID: 37052701
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Treatment Selection and Survival in Patients with Gray Zone lymphoma: A Comprehensive Population-Based Analysis.
    Samhouri Y; Jayakrishnan TT; Alnimer L; Bakalov V; Wegner RE; Khan C; Fazal S; Lister J
    Hematol Oncol Stem Cell Ther; 2023 Apr; 16(3):245-253. PubMed ID: 37023222
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.
    Kokalaki E; Ma B; Ferrari M; Grothier T; Hazelton W; Manzoor S; Costu E; Taylor J; Bulek A; Srivastava S; Gannon I; Jha R; Gealy R; Stanczuk L; Rizou T; Robson M; El-Kholy M; Baldan V; Righi M; Sillibourne J; Thomas S; Onuoha S; Cordoba S; Pule M
    Mol Ther; 2023 Jul; 31(7):2089-2104. PubMed ID: 36945773
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL.
    Collins MA; Jung IY; Zhao Z; Apodaca K; Kong W; Lundh S; Fraietta JA; Kater AP; Sun C; Wiestner A; Melenhorst JJ
    Cancer Res Commun; 2022 Sep; 2(9):1089-1103. PubMed ID: 36922932
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas.
    Moreno V; Vieito M; Sepulveda JM; Galvao V; Hernández-Guerrero T; Doger B; Saavedra O; Carlo-Stella C; Michot JM; Italiano A; Magagnoli M; Carpio C; Pinto A; Sarmiento R; Amoroso B; Aronchik I; Filvaroff E; Hanna B; Wei X; Nikolova Z; Braña I
    Nat Commun; 2023 Mar; 14(1):1359. PubMed ID: 36914652
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 18.